Changes in mucosal levels of transforming growth factor-alpha from the oxyntic region and ulcer site during duodenal ulcer healing with ranitidine or sucralfate.
Changes in the levels of transforming growth factor-alpha (TGF-alpha) in gastric mucosa during ulcer healing were studied in 24 patients with endoscopically confirmed duodenal ulcers, treated either with ranitidine (300 mg daily, at night) or with sucralfate (2 g twice daily). Endoscopic biopsies were taken from the gastric fundus and from the ulcer margin at baseline and after 7-10 days of treatment. TGF-alpha levels were determined by radioimmunoassay in paired samples from 22 patients (fundal) and 18 patients (duodenal). There were no significant changes in TGF-alpha levels in the fundus of the whole group or of either treatment group. At the ulcer site, however, there was a significant increase in TGF-alpha levels in the whole group (from 16.4 to 33 pg/mg protein (medians); P < 0.005), and an increasing trend was seen in both treatment groups but was statistically significantly only in the group treated with sucralfate (P < 0.03).
Louw
J A
JA
Gastrointestinal Clinic, University of Cape Town, Observatory, South Africa.
Modlin
I M
IM
Tang
L
L
Young
G O
GO
Lucke
W
W
Marks
I N
IN
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001706:Biopsy; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D005260:Female; D016481:Helicobacter Infections / Q000378:metabolism / Q000473:pathology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011899:Ranitidine / Q000627:therapeutic use*; D013392:Sucralfate / Q000627:therapeutic use*; D016211:Transforming Growth Factor alpha / Q000096:biosynthesis*
D000897:Anti-Ulcer Agents; D016211:Transforming Growth Factor alpha; D013392:Sucralfate; D011899:Ranitidine